Wegovy (semaglutide) and Zepbound (tirzepatide) are GLP-1 medications approved for weight management as well as other conditions.

Other GLP-1s are only approved for the management of certain conditions like type 2 diabetes, cardiovascular disease, kidney disease, and obstructive sleep apnea.

Novo Nordisk, the manufacturer of Wegovy, recommends starting at a weekly dose of 0.25 mg and increasing the dose every 4 weeks. The recommended maintenance dose is 2.4 mg once weekly, although some adults with obesity may increase to 7.2 mg once weekly if additional weight loss is needed.

Eli Lilly, the manufacturer of Zepbound, recommends starting at a weekly dose of 2.5 mg. It then recommends increasing to the next higher dose every 4 weeks until you reach the recommended maintenance dose or the maximum dose of 15 mg.

Your healthcare professional may adjust how quickly your dose is increased based on your response to the medication and any side effects you experience. Talk with them about the appropriate dosing schedule for you.